Patents by Inventor Takashi Akamizu

Takashi Akamizu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TEST METHOD FOR EVALUATING THE RISK OF ANTI-THYROID DRUG-INDUCED AGRANULOCYTOSIS, AND EVALUATION KIT
    Publication number: 20190316199
    Abstract: The present invention provides a test method and an evaluation kit for determining the risk of antithyroid drug-induced agranulocytosis. More particularly, it provides a test method for determining the risk of antithyroid drug-induced agranulocytosis, including testing susceptibility polymorphism to antithyroid drug-induced agranulocytosis, and determining the risk of antithyroid drug-induced agranulocytosis, and an evaluation kit for the risk of antithyroid drug-induced agranulocytosis, containing a polynucleotide capable of detecting susceptibility polymorphism to antithyroid drug-induced agranulocytosis.
    Type: Application
    Filed: December 3, 2018
    Publication date: October 17, 2019
    Inventors: Fumihiko Matsuda, Chikashi Terao, Takashi Akamizu, Hiroshi Yoshimura, Akira Miyauchi
  • TEST METHOD FOR EVALUATING THE RISK OF ANTI-THYROID DRUG-INDUCED AGRANULOCYTOSIS, AND EVALUATION KIT
    Publication number: 20160222453
    Abstract: The present invention provides a test method and an evaluation kit for determining the risk of antithyroid drug-induced agranulocytosis. More particularly, it provides a test method for determining the risk of antithyroid drug-induced agranulocytosis, including testing susceptibility polymorphism to antithyroid drug-induced agranulocytosis, and determining the risk of antithyroid drug-induced agranulocytosis, and an evaluation kit for the risk of antithyroid drug-induced agranulocytosis, containing a polynucleotide capable of detecting susceptibility polymorphism to antithyroid drug-induced agranulocytosis.
    Type: Application
    Filed: September 11, 2014
    Publication date: August 4, 2016
    Inventors: Fumihiko Matsuda, Chikashi Terao, Takashi Akamizu, Hiroshi Yoshimura, Akira Miyauchi
  • Method for treatment of hyperglycemia in a subject in need thereof
    Patent number: 7803768
    Abstract: A pharmaceutical for promoting neogenesis or regeneration of pancreatic ? cells which produces and secretes insulin and for promoting insulin production in ? cells, comprising ghrelin or a derivative thereof as an effective component.
    Type: Grant
    Filed: February 23, 2006
    Date of Patent: September 28, 2010
    Assignees: Kyoto University, Daiichi Sankyo Company Limited
    Inventors: Kenji Kangawa, Takashi Akamizu, Taiga Irako, Shuichi Koda, Naomi Wakabayashi
  • Promoter of Regeneration of Pancreatic B Cell, and Promoter of Insulin Production in Pancreatic B Cell
    Publication number: 20090143284
    Abstract: A pharmaceutical for promoting neogenesis or regeneration of pancreatic ? cells which produces and secretes insulin and for promoting insulin production in ? cells, comprising ghrelin or a derivative thereof as an effective component.
    Type: Application
    Filed: February 23, 2006
    Publication date: June 4, 2009
    Inventors: Kenji Kangawa, Takashi Akamizu, Taiga Irako, Shuichi Koda, Naomi Wakabayashi
  • Secretory thyroid stimulating hormone receptor, and method for assaying anti-thyroid stimulating hormone receptor antibody using the same
    Patent number: 6933364
    Abstract: A recombinant soluble human thyroid hormone receptor, comprising an extracellular domain moiety of a human thyroid hormone receptor, or a mutant thereof, being secretory, and having reactivity with an anti-human thyroid stimulating hormone receptor autoantibody; a composition for assaying an anti-human thyroid stimulating hormone receptor antibody, comprising the receptor and a carrier or diluent; a method for assaying an anti-human thyroid stimulating hormone receptor antibody, comprising reacting an anti-human thyroid stimulating hormone receptor antibody with the receptor; and a process for producing a recombinant soluble human thyroid hormone receptor which is secretory and has reactivity with an anti-human thyroid stimulating hormone receptor autoantibody, comprising infecting an insect cell with a recombinant baculovirus introduced with an extracellular domain moiety of a gene encoding a human thyroid hormone receptor or a mutant thereof, and culturing the infected cell.
    Type: Grant
    Filed: August 24, 2000
    Date of Patent: August 23, 2005
    Assignee: Tosoh Corporation
    Inventors: Yoshiyuki Hattori, Takashi Akamizu